ALX Oncology Holdings Inc.
Last updated September 27, 2026
Organization details
- Legal name
- ALX Oncology Holdings Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- South SAN Francisco
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- ALXO
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001810182
- EIN
- 85-0642577
Board of directors
-
Alan B. Sandler · DirectorSince 2024
-
Barbara Klencke · DirectorSince 2025
-
Chris H. Takimoto · DirectorSince 2025
-
Corey S. Goodman · DirectorSince 2023
-
Daniel J. Curran · DirectorSince 2025
-
Itziar Canamasas · DirectorSince 2023
-
J. Scott Garland · DirectorSince 2023
-
Jack Nielsen · DirectorSince 2023
-
Jason Lettmann · Director · CHIEF EXECUTIVE OFFICERSince 2023
-
Jaume Pons · Director · PRESIDENT & CSOSince 2023
-
Rekha Hemrajani · DirectorSince 2023
-
Sophia Randolph · Director · CHIEF MEDICAL OFFICERSince 2023
Chief executives
Jason Lettmann
· CHIEF EXECUTIVE OFFICER
Dates unknown
Jaume Pons
· President & CEO
Dates unknown
Director election results
Annual meeting of June 10, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
81.9%
-
99.9%
Board connections
5 of this board's directors also sit on 11 other boards.
- via J. Scott Garland and Rekha Hemrajani
- via Jack Nielsen
- via Rekha Hemrajani
- via J. Scott Garland
- via Jack Nielsen
- via Jack Nielsen
- via Rekha Hemrajani
- via J. Scott Garland
- via Barbara Klencke
- via Barbara Klencke
- via Daniel J. Curran
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $4,999,999
- 1 purchase by 1 insider
- Sold, last 12 months
- $42,588
- 7 sales by 2 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 17, 2026 | Wong Shelly Officer (SVP, FINANCE AND CAO) | Open-market sale | −573 | $1.93 | $1,106 |
| Aug 17, 2026 | Jason Lettmann Director, Officer (CHIEF EXECUTIVE OFFICER) | Open-market sale | −2,230 | $1.93 | $4,304 |
| Jul 1, 2026 | Wong Shelly Officer (SVP, FINANCE AND CAO) | Open-market sale | −1,404 | $2.04 | $2,864 |
| Mar 19, 2026 | Jason Lettmann Director, Officer (CHIEF EXECUTIVE OFFICER) | Open-market sale | −12,311 | $2.17 | $26,715 |
| Mar 19, 2026 | Pinto Shelly Officer (SVP, FINANCE AND CAO) | Open-market sale | −903 | $2.17 | $1,960 |
| Feb 18, 2026 | Pinto Shelly Officer (SVP, FINANCE AND CAO) | Open-market sale | −565 | $2.27 | $1,283 |
| Feb 17, 2026 | Jason Lettmann Director, Officer (CHIEF EXECUTIVE OFFICER) | Shares withheld for tax | −2,201 | $2.27 | $4,996 |
| Feb 2, 2026 | Corey S. Goodman Director, 10% owner | Open-market purchase | +3,184,713 | $1.57 | $4,999,999 |
| Jan 6, 2026 | Pinto Shelly Officer (SVP, FINANCE AND CAO) | Open-market sale | −3,925 | $1.11 | $4,357 |
| Sep 17, 2025 | Jason Lettmann Director, Officer (CHIEF EXECUTIVE OFFICER) | Open-market purchase | +71,163 | $1.08 | $76,856 |
| Sep 16, 2025 | Jason Lettmann Director, Officer (CHIEF EXECUTIVE OFFICER) | Open-market purchase | +21,070 | $1.07 | $22,545 |
| Aug 18, 2025 | Shantharam Harish Officer (Chief Financial Officer) | Open-market purchase | +75,000 | $0.78 | $58,500 |
| Aug 15, 2025 | Pinto Shelly Officer (SVP, FINANCE AND CAO) | Open-market sale | −611 | $0.64 | $391 |
| Aug 15, 2025 | Jason Lettmann Director, Officer (CHIEF EXECUTIVE OFFICER) | Open-market sale | −2,382 | $0.64 | $1,524 |
| Jul 7, 2025 | Pinto Shelly Officer (SVP, FINANCE AND CAO) | Open-market sale | −2,011 | $0.45 | $905 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.